Campos Susana M
Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA.
Breast Cancer Res Treat. 2005;89 Suppl 1:S1-7. doi: 10.1007/s10549-005-0142-0.
Treatment approaches for early breast cancer continue to evolve as key trials involving adjuvant chemotherapy and hormonal therapy provide results that can inform clinical practice. The administration of a taxane, either in combination with or following doxorubicin and cyclophosphamide, has been shown to significantly improve disease-free survival (DFS) and overall survival (OS). In addition, a dose-dense treatment approach (reducing the inter-treatment interval) was found to be more effective than conventionally scheduled treatment in terms of DFS and OS. As treatment schemes evolve, supportive care becomes increasingly important to manage the toxicities of chemotherapy, such as anemia and impaired cognition. In addition to chemotherapy, the use of hormonal therapy continues to evolve, with studies demonstrating the benefit of the aromatase inhibitors and serum estrogen receptor down-regulation.
早期乳腺癌的治疗方法不断发展，因为涉及辅助化疗和激素治疗的关键试验提供了可为临床实践提供参考的结果。紫杉烷与阿霉素和环磷酰胺联合使用或在其后使用，已被证明可显著提高无病生存期（DFS）和总生存期（OS）。此外，在DFS和OS方面，剂量密集治疗方法（缩短治疗间隔时间）被发现比传统治疗方案更有效。随着治疗方案的不断发展，支持性护理对于管理化疗毒性（如贫血和认知障碍）变得越来越重要。除化疗外，激素治疗的应用也在不断发展，研究表明芳香化酶抑制剂和血清雌激素受体下调具有益处。
